<DOC>
	<DOCNO>NCT01635855</DOCNO>
	<brief_summary>A prospective , open-label 1-month post-approval study evaluate short term safety Belotero® Balance re-treatment nasolabial fold .</brief_summary>
	<brief_title>Belotero Post Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>1 . Was participant Belotero® Balance premarket IDE clinical trial Belotero Balance Fitzpatrick Skin Type IVVI Study . 2 . Is candidate bilateral nasolabial fold retreatment Belotero® Balance . 3 . Understands accepts obligation receive facial procedure enrollment 1 month optimal correction current study . 4 . Understands accepts obligation comply require followup visit logistically able meet study requirement . 1 . Has receive surgery either nasolabial fold . 2 . Has receive within past 6 month nonpermanent filler ( e.g . hyaluronic acid , CaHA ) neurotoxin zygomatic arch . 3 . Has receive time permanent filler ( e.g . polylactic acid , PMMA , silicone ) zygomatic arch . 4 . Has receive within past 6 month dermal resurfacing procedure ( e.g . medium/deep chemical peel , dermabrasion treatment , ablative laser resurface ) noninvasive skintightening ( e.g . Thermage ) zygomatic arch . 5 . Has receive past 2 week prescription facial wrinkle therapy ( e.g. , RENOVA® ) , topical steroid , skin irritate topical preparation , pigment agent ( selftanning agent ) zygomatic arch . 6 . Has receive past 2 month plan receive study immunosuppressive medication systemic steroid ( intranasal / inhale steroid acceptable ) . 7 . Has acute inflammatory process infection , history chronic recurrent infection inflammation potential interfere study result increase risk adverse event . 8 . Has know bleed disorder use medication reduces blood coagulation , ( e.g . aspirin , nonsteroidal antiinflammatory drug , warfarin ) may increase risk bleed treatment session . 9 . Has know history severe allergy manifest history anaphylaxis ; history presence multiple severe allergy . 10 . Has know allergy hypersensitivity hyaluronic acid preparation , gram positive bacterial protein Belotero® Belotero® derivative . 11 . Has know history hyper hypopigmentation nasolabial fold , keloid formation , hypertrophic scarring . 12 . Is female childbearing potential ( e.g . postmenopausal least one year hysterectomy tubal ligation ) pregnant , lactate plan become pregnant study use medically effective birth control . 13 . Has medical condition potential interfere study increase risk adverse event . 14 . Is enrolled plan enroll competitive interfering study . 15 . Is employee direct relative employee investigational site study sponsor . 16 . All Fitzpatrick skin type eligible study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>